弥漫大B细胞淋巴瘤部分免疫表型与CARMA1基因表达、临床病理特征的关系  

Relationship between immunophenotype and the expression of CARMA1,clinicopathologic features in diffuse large B cell lymphoma

作　　者：龙义国[1] 陈玉梅[1] 杨文秀[1] 钟愉[1] 孟青[1] 裴媛媛[1] 

机构地区：[1]贵阳医学院,贵阳550004

出　　处：《山东医药》2011年第4期25-26,29,共3页Shandong Medical Journal

基　　金：贵州省社会发展攻关项目基金[SY(2010)3054];贵州省科学技术基金资助项目[J(2009)2299]

摘　　要：目的比较CD10、Bcl6和MUM1全阳性和全阴性表达的弥漫大B细胞淋巴瘤(DLBCL)病例的临床病理特征、预后和CARMA1基因表达的差异。方法用HE和免疫组化染色筛选出27例CD10、Bcl6和MUM1全阳性或全阴性表达的DLBCL病例,检测肿瘤细胞Ki67表达水平,收集其临床病理资料并随访,RT-PCR技术检测肿瘤组织中CARMA1 mRNA表达并进行半定量分析。结果与CD10、Bcl6和MUM1全阴性组比较,全阳性组病例Ki67表达率升高,临床分期较晚,中位生存时间缩短,CARMA1 mRNA表达水平有升高的趋势。结论 CD10、Bcl6和MUM1全阳性表达的DLBCL病例的临床过程和预后较全阴性表达组差,CARMA1可能在全阳性DLBCL中存在过表达并参与病变发生发展过程。Objective To investigate the difference in the clinicopathologic features,prognosis and expression of CARMA1 gene between CD10,Bcl6 and MUM1 postive and negative expression group in diffuse large B cell lymphoma（DLBCL） cases.Methods Twenty-seven cases with DLBCL,which were CD10,Bcl6 and MUM1 postive or negative expression.The clinicopathological data of these cases were collected.CARMA1 mRNA level was detected by RT-PCR method.Follow-up and statistical analysis were done.Results Compared with CD10,Bcl6 and MUM1 negative expression group,patients in positive expression group had higher expression of Ki67,later staging,shorter survival time.CARMA1 mRNA level had an increasing trend in positive group.Conclusions DLBCL cases expressing CD10,Bcl6,MUM1 have a poor clinical course and prognosis.Over expression of CARMA1 maybe associate with the pathogenesis and progress in DLBCL with CD10,Bcl6,MUM1 postive expression.

关 键 词：淋巴瘤 大细胞 弥漫型 免疫表型分型 CARMA1基因 预后 

分 类 号：R733.4[医药卫生—肿瘤]